# Sofinnova Investments

> Sofinnova Investments is a VC fund backing Biotechnology and Health Care. See 220 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 220
- Last investment: Aug 2026
- Lead investor: 30%
- Fund size: $650M
- Last fund: Oct 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sofinnova-ventures/
- X (Twitter): http://twitter.com/Sofinnova
- Website: http://www.sofinnova.com

Sofinnova Investments is a VC fund in Menlo Park focused on Biotechnology and Health Care. Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to helpentrepreneurs build successful, global businesses.

## Contacts

5 contacts available for Sofinnova Investments. Shizune tracks 15 team members at Sofinnova Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sofinnova-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.3M–$115M |
| Series B | $15M–$150M |
| Series C | $15M–$94M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 102 | 46% |
| Health Care | 64 | 29% |
| Pharmaceutical | 46 | 21% |
| Medical | 43 | 20% |
| Therapeutics | 42 | 19% |

64 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 51 | 23% |
| Series A | 45 | 20% |
| Series C | 32 | 15% |
| Funding Round | 27 | 12% |
| Series D | 18 | 8% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 100 | 45% |
| France | 9 | 4% |
| Switzerland | 4 | 2% |
| United Kingdom | 4 | 2% |
| The Netherlands | 3 | 1% |

13 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jakob Dupont | Executive Partner | 3 | https://shizune.co/investors/profile/jakob-dupont-e61e |
| James Healy | General Partner & President | 25 | https://shizune.co/investors/profile/james-i-healy |
| Jonathan Leff | Executive Partner, Private Equity | 3 | https://shizune.co/investors/profile/jonathan-leff-6bb8 |
| Lesley Weber | San Diego Office Manager & EA | 0 | https://shizune.co/investors/profile/lesley-weber |
| Maha Radhakrishnan | Executive Partner | 2 | https://shizune.co/investors/profile/maha-radhakrishnan |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| Claris Biotherapeutics | Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M | Series B | Jul 28, 2026 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $165M | Series A | Oct 09, 2025 |  |
| Star Therapeutics | Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M | Series D | Sep 30, 2025 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M | Series B | Sep 04, 2025 |  |
| ARTBIO | ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M | Series B | Jul 29, 2025 |  |
| Atsena Therapeutics | Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $150M | Series C | Apr 02, 2025 |  |

10 of 220 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 19 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 19 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 16 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 15 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 15 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 13 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)

## FAQ

### What does Sofinnova Investments invest in?

Sofinnova Investments invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 220 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sofinnova Investments's check size?

Sofinnova Investments typically joins rounds of $7.3M–$115M at Series A, $15M–$150M at Series B and $15M–$94M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sofinnova Investments participates in.

### How do I contact Sofinnova Investments?

Public channels for Sofinnova Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sofinnova Investments?

The team at Sofinnova Investments includes Jakob Dupont (Executive Partner), James Healy (General Partner & President) and Jonathan Leff (Executive Partner, Private Equity), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co